摘要
[目的]评价Iressa治疗晚期难治性非小细胞肺癌(NSCLC)的疗效、中位生存期、疾病进展时间、及对生活质量的影响,分析与疗效和生存期可能相关的因素。[方法]40例经病理或细胞学证实的复治的Ⅲb～Ⅳ期NSCLC,每日口服IRESSA250mg,直至死亡或出现严重不良反应或病灶进展。[结果]病灶总缓解率37.5%,其中两肺弥漫浸润性转移者缓解率高达47.6%。症状改善率为65%,中位生存期为3个月,疾病进展时间为3个月。症状明显改善患者中位生存期为5个月,疾病进展时间为5个月。服药28天KPS评分从50.50提高到61.38,无Ⅲ～IV级毒性反应。[结论]口服IRESSA使用方便,毒性小,起效快。对复治的局部晚期和转移性非小细胞肺癌有一定疗效。症状好转比病灶缓解对生存期更有益。
To observe the response rate, survival time,time to progressio n,quality of life and toxicity of ZD1839 for the treatment of stage Ⅲb~Ⅳ non-small cell lung cancer(NSCLC) and to analyse the factors related to efficacy a nd survival.Forty cases with stage Ⅲb~Ⅳ NSCLC pathologically proved w ere enrolled in this study.Oral ZD1839 250mg daily were given to patients with r efractory advanced NSCLC until severe toxicity or disease or progress occurred. The overall response rate was 37.5%.The response rate was 47.6% in pa tients with bilateral lung metastasis.Disease-related symptom improvement was de monstrated in approximately 65%.Median survival time(MST)and median time to dise ase progression(TTP)were both 3 months.MST and TTP in patients with symptom imp rovement of patient were both 5 months.The Karnofsky improved significantly from 50.50 to 61.38 after 28 days treatment.No 3~4 degree of toxicity was observed.[Conclusion]Oral ZD1839 is effective with low toxicity and convenient administrat ion for previously treated,local advanced and metastatic NSCLC.
出处
《中国肿瘤》
CAS
2004年第10期625-628,共4页
China Cancer
